X
22Jan

Blog: Cooley’s 2020 Life Sciences M&A Year in Review

Cooley LLP | | Return|
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By: Cooley LLP
Source Url: https://www.jdsupra.com/legalnews/blog-cooley-s-2020-life-sciences-m-a-6599890/

Related

Naranjo v. Spectrum Security Services Denies Derivative Waiting Time Penalties and Wage Statement Penalties in Meal and Rest Break Actions

It’s no secret that California is typically viewed as the most employee-friendly state in the count...

Read More >

New York Targets Members of Out-of-State LLCs in New Wage Theft Bill

Effective February 10, 2020, the top ten members of an out-of-state limited liability company (“LLC...

Read More >

Supplying Wrong Construction Materials Resulting in Rip-and-Tear Damage Not an “Occurrence,” 7th Circuit Holds

The construction contract calls for International Building Code-compliant lumber. The insured doesn’...

Read More >

363 Sales as a Health Care M&A Tool, Part 2 – Pros and Cons for Buyers and Sellers

Over the summer, we wrote about why health care companies may want to consider buying assets out of ...

Read More >

Appeals Board Clarifies Medical-Legal Lien Burden of Proof

The Workers’ Compensation Appeals Board (WCAB) issued a unanimous en banc decision on November 14, ...

Read More >

An Aging Construction Workforce: Recognition And Response

The number of workers aged 55 and over is increasing, while the number of workers under the age of 2...

Read More >